Dermatology
ARS gears up for neffy US approval
ARS Pharmaceuticals expects to launch neffy (epinephrine nasal spray) in H2 2024, for which the company plans to submit a…
FDA approves Boehringer’s SPEVIGO for psoriasis treatment
The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis…
China NMPA approves KeChow’s tunlametinib for melanoma
The China National Medical Products Administration (NMPA) has approved KeChow Pharma's tunlametinib (HL-085) for treating patients with neuroblastoma ras viral…
Almirall to license Eloxx’s ZKN-013 for rare skin conditions
Almirall has signed an exclusive licence agreement to gain worldwide rights for Eloxx Pharmaceuticals’ ZKN-013 for rare dermatological disease indications.…
Galderma sets price range for supersized $2.6bn IPO in Europe
Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on…
Sanofi’s amlitelimab shows best-in-class response in atopic dermatitis
Sanofi has announced encouraging findings from the second part of a study with the OX40 antibody amlitelimab, which showed sustained…
Almirall licenses IL-21 antibody from Novo Nordisk
Almirall has signed an exclusive licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s interleukin-21 (IL-21)-hindering monoclonal antibody,…
Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan
Sanofi and Regeneron Pharmaceuticals have received yet another approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for…
Alys Pharmaceuticals announces launch with $100m funding
Alys Pharmaceuticals has announced its launch with a research and development (R&D) immuno-dermatology focused pipeline backed by a $100m financing…
Almirall and Microsoft partner for dermatological drug development
Pharmaceutical company Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology. The three-year…